NFKB1 and metabolic dysfunction-associated steatotic liver disease: The acetate stimulates the FFA receptor 2 (FFAR2), which may reduce the NAFLD pathogenesis and progression by reducing insulin resistance, NF-κB and TNF-α-mediated inflammation, and expression of collagen promoters [131].